Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | LCP2 | Q13094 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12942479 | 0.79 | KDM5A (0.33) | KDM5A | |
| SCHEMBL25915911 | 0.77 | SMPD3 (0.33) | SMPD3 | |
| SCHEMBL15360079 | 0.75 | SMPD3 (0.44) | SMPD3CRHR1NCF1DYRK1ACYP1A2 | |
| SCHEMBL15032488 | 0.73 | KDM5A (0.35) | KDM5A | |
| SCHEMBL10643795 | 0.73 | KDM5A (0.33) | KDM5ADYRK1A | |
| SCHEMBL24879570 | 0.73 | SMPD3 (0.40) | SMPD3CRHR1NCF1 | |
| SCHEMBL784164 | 0.73 | ADORA2A (0.36) | KDM5ADYRK1A | |
| SCHEMBL24896141 | 0.73 | SMPD3 (0.42) | SMPD3CRHR1NCF1 | |
| SCHEMBL11323732 | 0.73 | KDM5A (0.35) | KDM5A | |
| SCHEMBL15948779 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240182-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-18 | — | — | US | disclosed |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209373-A1 | ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-02-29 | — | — | US | disclosed |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-02-29 | — | — | US | disclosed |
| WO-2023192977-A2 | SNCA-TARGETING SIRNA COMPOSITIONS FOR TREATING SNCA-ASSOCIATED DISEASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230287424-A1 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | BANK OF AMERICA, N.A. | 2023-09-14 | — | — | US | disclosed |
| US-20230272382-A1 | COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES | BANK OF AMERICA, N.A. | 2023-08-31 | — | — | US | disclosed |
| WO-2022066847-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2021252557-A1 | RNAI COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021202443-A2 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | ALNYLAM PHARMACEUCTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021202511-A2 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021195307-A1 | CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20210238594-A1 | COMPOSITIONS AND METHODS FOR IMPROVING STRAND BIASED | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| WO-2021119226-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-11034957-B2 | Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| WO-2021087036-A1 | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20200339991-A1 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287424-A1 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | MTREX, RNASEH1, RNASE1 | SMPD3 371/4885CRHR1 2877/4885NCF1 1358/4885 |
| US-20200339991-A1 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | APP, APBA1, PSEN1 | SMPD3 152/4885CRHR1 4404/4885NCF1 1486/4885 |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | DPP4, DPP3, DPP7 | SMPD3 372/4885CRHR1 3262/4885NCF1 4005/4885 |
| US-11034957-B2 | Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof | APP, APBA1, PSEN1 | SMPD3 152/4885CRHR1 4404/4885NCF1 1486/4885 |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ADAR, AGO2, METTL16 | SMPD3 1117/4885CRHR1 4012/4885NCF1 4319/4885 |
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | CHI3L1, CHIA, CHI3L2 | SMPD3 190/4885CRHR1 2971/4885NCF1 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.